Share：
Share this content in WeChat
X
[Chinese][PDF]192087
• Review •
The application of magnetic resonance imaging in evaluating efficacy of neoadjuvant chemotherapy for breast cancer
ZHANG Dan-dan  HUA Jia 

DOI:10.12015/issn.1674-8034.2017.12.015.


[Abstract] With its advantage of high sensitivity and accuracy, magnetic resonance imaging (MRI) has been the most compelling imaging test in evaluating the efficacy of neoadjuvant chemotherapy (NAC) of breast cancer and widely accepted by the clinic. However, due to the high heterogeneity and the various shrinking patterns after chemotherapy, the current MRI assessment regimens could not help clinicians to formulate therapy plan individually. Therefore, it has become a close concern for how MRI to evaluate the efficacy of NAC accurately. Reviewing of the application of MRI in different phase of neoadjuvant chemotherapy, we will discuss the appropriate MRI testing times and imaging index and then look forward to future directions in this area based on tumor heterogeneity.
[Keywords] Breast neoplasms；Neoadjuvant chemotherapy；Magnetic resonance imaging

ZHANG Dan-dan Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China

HUA Jia* Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China

*Correspondence to: Hua J, E-mail:Jill_huajia@163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This work was part of Medical Engineering Cross Research Foundation of Shanghai Jiaotong University No. YG2014ZD05
Received  2017-06-30
Accepted  2017-09-06
DOI: 10.12015/issn.1674-8034.2017.12.015
DOI:10.12015/issn.1674-8034.2017.12.015.

[1]
中国抗癌协会乳腺癌专业委员会.中国进展期乳腺癌共识指南(CABC 2015).癌症进展, 2015, 13(3): 223-245.
[2]
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 365(9472): 1687-1717.
[3]
Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol, 2012, 19(5): 1508-1516.
[4]
Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol, 2015, 22(5): 1416-1424.
[5]
Kostopoulos SA, Vassiou KG, Lavdas EN, et al. Computer-based automated estimation of breast vascularity and correlation with breast cancer in DCE-MRI images. Magn Reson Imaging, 2017, 35: 39-45.
[6]
Croshaw R, Shapiro-Wright H, Svensson E, et al. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol, 2011, 18(11): 3160-3163.
[7]
Xu HD, Zhang YQ. Evaluation of the efficacy of neoadjuvant hemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging. Neoplasma, 2017, 64(3): 430-436.
[8]
Minarikova L, Bogner W, Pinker K, et al. Investigating the prediction value of multiparametric magnetic resonance imaging at 3.0 T in response to neoadjuvant chemotherapy in breast cancer. Eur Radiol, 2017, 27(5): 1901-1911.
[9]
赵莉芸，张仁知，周纯武,等.动态增强MR定量分析早期预测乳腺癌新辅助化疗疗效的研究.中华放射学杂志, 2013, 47(8): 704-708.
[10]
Shin HJ, Baek HM, Ahn JH, et al. Prediction of pathologicresponse to neoadjuvant chemotherapy in patients with breastcancer using diffusion-weighted imaging and MRS. NMR Biomed, 2012, 25(12): 1349-1359.
[11]
高影，程流泉，刘梅,等. MRI对局部进展期乳腺癌新辅助化疗早期疗效评价.中国医学影像学杂志, 2012, 20(5): 32l-324．
[12]
汪晓红，彭卫军，谭红娜,等.磁共振弥散加权成像监测乳腺癌新辅助化疗疗效的应用价值.中华肿瘤杂志, 2010, 32(5): 377-381.
[13]
Richard R, Thomassin I, Chapellier M, et al. Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol, 2013, 23(9): 2420-2431．
[14]
Bufi E, Belli P, Costantini M, et al. Role of the apparent diffusion coefficient in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Breast Cancer, 2015, 15(5): 370-380．
[15]
熊发奎，龚良庚. MRI不同技术在乳腺癌新辅助化疗评价的应用进展.中国临床医学影像杂志, 2017, 28(2): 145-187.
[16]
Che S, Zhao X, Ou Y, et al. Role of the intravoxel incoherent motion diffusion weighted imaging in the pre-treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer. Medicine, 2016, 95(4): e2420.
[17]
Kassas HE, Helal M, Abourabia A, et al. Role of MRI diffusion as an adjunct to contrast enhanced MRI of the breast for the evaluation of breast cancer patients receiving neoadjuvent chemotherapy. Egyptian J Radiol Nuclear Med, 2016, 47(4): 1721-1732.
[18]
李瑞敏，顾雅佳，彭卫军,等.定量动态增强磁共振评估乳腺癌新辅助化疗疗效的应用研究.中国癌症杂志, 2016, 26(8): 623-628.
[19]
Zheng D, Yue Q, Ren W, et al. Early responses assessment of neoadjuvant chemotherapy in nasopharyngeal carcinoma by serial dynamic contrast-enhanced MR imaging. Magn Reson Imaging, 2017, 35: 125-131.
[20]
Iwasa H, Kubota K, Hamada N, et al. Early prediction of response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and gray-scale ultrasonography. Oncol Rep, 2014, 31(4): 1555-1560.
[21]
Loo CE, Teertstra HJ, Rodenhuis S, et al. Dynamic contrast enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol, 2008, 191(5):1331-1338.
[22]
Cheung YC, Chen SC, Hsieh IC, et al. Multidetector computed tomography assessment on tumor size and nodal status in patients with locally advanced breast cancer before and after neoadjuvant chemotherapy. Eur J Surg Oncol, 2006, 32(10): 1186-1190.
[23]
Fukuda T, Horii R, Gomi N, et al. Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype. Springer Plus, 2016, 5(1): 152.
[24]
朱振国，姜熳.核磁共振全身弥散加权成像(WB-DWI)在乳腺癌患者术前化疗疗效评估中的应用价值.肿瘤学杂志, 2016, 22(6): 443-447.
[25]
Hahn SY, Ko EY, Han BK, et al. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy. Eur J Radiol, 2014, 83(2): 283-288.
[26]
李曼曼，刘慧，徐斌,等.基于磁共振成像乳腺癌不同分子分型的肿瘤退缩模式初探.中华肿瘤防治杂志, 2016, 23(15): 1016-1020.
[27]
Ballesio L, Gigli S, Di Pastena F, et al. Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy. Tumour Biol, 2017, 39(3): 1010428317694540.

PREV Progress of diffusion tensor imaging in acute spinal cord injury
NEXT Analysis of magnetic resonance imaging quality control in bone and joint system
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn